|
|
200 Connell Drive #1500
Berkeley Heights, NJ 07922 USA
phone:+1 (908) 517 7330
fax:+1 (866) 271 3466
|
|
| Symbol |
CYCC |
| Exchange |
NASDAQ |
| Founded |
1996 |
| Employees |
23 |
|
|
| www.cyclacel.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Drugs to treat human cancers and other serious diseases |
|
| Management |
| Spiro Rombotis, President and Chief Executive Officer, Director; Paul McBarron, Executive Vice President, Finance and Chief Operating Officer, Secretary and Director; Professor David Glover, PhD FRS FRSE, Chief Scientist, Polgen Division; Judy Chiao, M.D., Vice President Clinical Development and Regulatory Affairs; Susan Davis, Ph.D., Director, Business Development; Robert Sosnowski, Vice President, Sales & Marketing |
| |
|
|
|
|
|
|
|
| Keywords |
| biopharmaceutical company, seliciclib, human cancers, clinical development, sapacitabine |
|
|
|
| Description |
|
Cyclacel Pharmaceuticals Inc. is a biopharmaceutical company primarily focused on the development of its orally-available anticancer agents that target the cell cycle. Sapacitabine (CYC682) is a cell cycle-modulating nucleoside analop that interferes with DNA synthesis by introducing single-strand DNA breaks leading to the arrest of the cell division cycle at G2 phase; it is entering Phase III development for the treatment of Acute Myeloid Leukemia in the elderly and is in Phase II studies for myelodysplastic syndromes and lung cancer. Seliciclib (CYC202) is a novel, first-in-class CDK-inhibitor that selectively inhibits multiple enzyme targets that are central to the process of cell division and cell cycle control, thereby inducing apoptosis; Seliciclib is in Phase II studies for the treatment of lung cancer and nasopharyngeal cancer and is in a Phase I trial in combination with Sapacitabine. Overall, Cyclacel’s drug pipeline covers all four phases of the cell cycle, which the Company believes will improve its chances of successfully developing drugs that work on their own, in conjunction with approved chemotherapies, or in combination with other target anticancer drugs. This later-stage biotechnology company has also developed compound series for potential usage in the treatments of Inflammatory Kidney Disease, Type 2 Diabetes, and HIV. |
|
| Products / Services |
Sapacitabine, a cell cycle modulating nucleoside analog, is in Phase 2 studies for the treatment of acute myeloid leukemia in the elderly, myelodysplastic syndromes and lung cancer and in Phase 1 in combination with seliciclib.
Seliciclib, a CDK (cyclin dependent kinase) inhibitor, is in Phase 2 for the treatment of lung and nasopharyngeal cancer. CYC116, an Aurora kinase and VEGFR2 inhibitor, is in Phase 1 in patients with solid tumors.
|
|
| Technology / Differentiation |
| The cell cycle, the process by which cells progress and divide, lies at the heart of cancer. In normal cells, the cell cycle is controlled by a complex series of signaling pathways by which a cell grows, replicates its DNA and divides. This process also includes mechanisms to ensure errors are corrected, and if not, the cells commit suicide (apoptosis). In cancer, as a result of genetic mutations, this regulatory process malfunctions, resulting in uncontrolled cell proliferation |
|
| Market / Customers |
Cyclacels ALIGN Pharmaceuticals subsidiary markets directly in the U.S. Xclair Cream for radiation dermatitis, Numoisyn Liquid and Numoisyn Lozenges for xerostomia.
|
|
| Strategy |
Cyclacel's strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a portfolio of commercial products and a development pipeline of novel drug candidates.
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
